Donate Help Contact The AHA Sign In Home
American Heart Association
Stroke
Search: search_blue_button Advanced Search
Stroke. 2007;38:791-793
doi: 10.1161/01.STR.0000252090.44428.82
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Zivin, J. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Zivin, J. A.
Right arrowPubmed/NCBI databases
Medline Plus Health Information
*Stroke
Related Collections
Right arrow Other Treatment
Right arrow Neuroprotectors
Right arrow Other Stroke Treatment - Medical

(Stroke. 2007;38:791.)
© 2007 American Heart Association, Inc.


New Approaches to Clinical Trials in Neuroprotection: Introduction

Clinical Trials of Neuroprotective Therapies

Justin A. Zivin, MD, PhD

From the University of California San Diego, La Jolla, Calif.

Correspondence to Justin A. Zivin, University of California San Diego, 9500 Gilman Dr, La Jolla, CA 92093-0624. E-mail jzivin{at}ucsd.edu

Abstract

There have been numerous failures in the field of acute stroke therapy over many years, but the first large clinical trial showing preliminary indications of efficacy and safety of a neuroprotective drug, NXY-059, has now been fully reported. If confirmed, it will mean that a second therapy for acute stroke has been identified and neuroprotective drug development as a class can proceed. Additionally, a new class of drugs, HMG CoA-reductase inhibitors (statins), specifically high-dose atorvastatin, has been shown to be safe and effective for secondary stroke prevention. This drug should now become a regular part of stroke patient care.


Key Words: acute Rx • acute stroke • free radicals • prevention • statins




This article has been cited by other articles:


Home page
J. Pharmacol. Exp. Ther.Home page
R. C. Bucelli, E. A. Gonsiorek, W.-Y. Kim, D. Bruun, R. A. Rabin, D. Higgins, and P. J. Lein
Statins Decrease Expression of the Proinflammatory Neuropeptides Calcitonin Gene-Related Peptide and Substance P in Sensory Neurons
J. Pharmacol. Exp. Ther., March 1, 2008; 324(3): 1172 - 1180.
[Abstract] [Full Text] [PDF]